ابتكر العلماء في معهد سانفورد بورنهام بريبيس للاكتشافات الطبية دواء يمكنه إغراء الخلايا الجذعية للأنسجة التالفة وتحسين فعالية العلاج — a scientific first and major advance for the field of regenerative medicine. The discovery, published in the Proceedings of the National Academy of Sciences (PNAS), could improve current stem cell therapies designed to treat such neurological disorders as spinal cord injury, السكتة الدماغية, التصلب الجانبي الضموري?(AS) and other neurodegenerative disorders; and expand their use to new conditions, such as heart disease or arthritis.

Toxic cells (green) disappeared when mice with a neurodegenerative condition received both therapeutic stem cells (red) and the drug SDV1a-which corresponded with longer lives and delayed symptom onset. These results suggest that SDV1a can be used to improve the efficacy of stem cell treatments.

The ability to instruct a stem cell where to go in the body or to a particular region of a given organ is the Holy Grail for regenerative medicine,” says Evan Y. Snyder, م. Ph.D., professor and director of the Center for Stem Cells & Regenerative Medicine at Sanford Burnham Prebys and senior author of the study. “الآن, for the first time ever, we can direct a stem cell to a desired location and focus its therapeutic impact.


NBScience

منظمة بحثية العقد

العلاج بالخلايا الجذعية